Upload
Featured Recent Articles Topics Login Upload

Search Results for 'P2y12-Rivaroxaban'

P2y12-Rivaroxaban published presentations and documents on DocSlides.

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
by celsa-spraggs
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by giovanna-bartolotta
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by ellena-manuel
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:
Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:
by giovanna-bartolotta
Rivaroxaban Plus Aspirin in Patients With and Wit...
Rivaroxaban or Aspirin for Extended Treatment of Venous Thr
Rivaroxaban or Aspirin for Extended Treatment of Venous Thr
by yoshiko-marsland
(EINSTEIN CHOICE). Ryan Sparks, . PharmD. , BCPS....
Rivaroxaban compared with enoxaparin for the prevention of
Rivaroxaban compared with enoxaparin for the prevention of
by luanne-stotts
Alexander T Cohen . On behalf of the MAGELLAN Ste...
DUAL ANTIPLATELET THERAPY
DUAL ANTIPLATELET THERAPY
by mary
(DAPT) . BHAVI SHAH, DNP, APRN, ANP-C. UNIVERSITY ...
Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding
Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding
by kyle585
Paul P. . Dobesh. , . Pharm.D. , FCCP, BCPS, BCCP....
Review on NOACs Studies Dr.
Review on NOACs Studies Dr.
by BlessedBeyondMeasure
Kourosh. . Sadeghi. Tehran University of medical ...
MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,
MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,
by HoneyBun
VTE death. ) for . rivaroxaban. vs. . enoxaparin....
X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the
X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the
by LittleMissPerfect
rivaroxaban. group vs. 1.02% of the vitamin K ant...
Thromboembolic protocols
Thromboembolic protocols
by cecilia
& safe anticoagulant prescribing. July 2020. D...
Rivaroxaban in stable peripheral or carotid artery disease
Rivaroxaban in stable peripheral or carotid artery disease
by basidell
Sonia Anand, on . behalf of the COMPASS Steering C...
A ssessment of D ual antiplatelet therapy versus
A ssessment of D ual antiplatelet therapy versus
by coursion
R. ivaroxaban . I. n atrial . F. ibrillation patie...
Ima A. Kusuma , MD, FIHA
Ima A. Kusuma , MD, FIHA
by hirook
“JIH. ” Hospital, Yogyakarta, Indonesia. The U...
A ssessment of D ual antiplatelet therapy versus
A ssessment of D ual antiplatelet therapy versus
by stefany-barnette
A ssessment of D ual antiplatelet therapy versus...
Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators
Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators
by yoshiko-marsland
Dr. Phil Wells on behalf of the EINSTEIN CHOICE ...
CAD/PAD in Primary Care CV Risk in Stable Outpatients
CAD/PAD in Primary Care CV Risk in Stable Outpatients
by stefany-barnette
Stratified by Baseline CV Risk Category. Aspirin ...
A New Era in Anticoagulation Management
A New Era in Anticoagulation Management
by alexa-scheidler
Allyson Sarigianis, Pharm.D.. October 19, 2013. O...
Stroke, Bleeding, and
Stroke, Bleeding, and
by lois-ondreau
Mortality Risks . in . Elderly Medicare Beneficia...
New Oral Anticoagulant
New Oral Anticoagulant
by mitsue-stanley
R2 Patcharee Seesongsom. R2 . Sirada. . Phoja...
R eal-world
R eal-world
by liane-varnes
EVI. dence. on . S. troke prevention . I. n pati...
A New Era in Anticoagulation Management
A New Era in Anticoagulation Management
by debby-jeon
Allyson Sarigianis, Pharm.D.. October 19, 2013. O...
Novel Oral Anticoagulants
Novel Oral Anticoagulants
by natalia-silvester
(. N. OAC). Dan . Moellentin. , . PharmD. , BCPS,...
Recent ACS: STEMI, NSTEMI, UA
Recent ACS: STEMI, NSTEMI, UA
by danika-pritchard
Stabilized 1-7 Days Post-Index Event. Exclusions:...
Fanaroff et al. JAMA Cardiol
Fanaroff et al. JAMA Cardiol
by alyssa
. 2020 . Background. Medication persistence . is ....
Management of Myocardial
Management of Myocardial
by clara
. infarction. . NSTEMI Guidelines. Benoit Lattuca...
Cangrelor : Friend or Foe? -
Cangrelor : Friend or Foe? -
by ariel
Cangrelor. : Not the CHAMPION We Hoped For. James ...
Aspirin in 2022: A New Aspirin for a New Chapter
Aspirin in 2022: A New Aspirin for a New Chapter
by belinda
March 28, 2022. Disclosures. Present Research/Gran...
Antiplatelet Agents Mohammad Sistanizad
Antiplatelet Agents Mohammad Sistanizad
by blindnessinfluenced
Associate Professor of Clinical Pharmacy,. SBMU. C...
Prasugrel vs ticagrelor in acute coronary syndromes
Prasugrel vs ticagrelor in acute coronary syndromes
by tawny-fly
Giuseppe . Biondi-Zoccai. , MD. Sapienza Universi...
When should we start a
When should we start a
by myesha-ticknor
P2Y. 12. inhibitor . in patients with an acute c...
Novel antithrombotic agents in acute coronary syndromes: be
Novel antithrombotic agents in acute coronary syndromes: be
by jane-oiler
n . P2Y12 inhibitors. Giuseppe Biondi Zoccai. Sap...
Anisah Ahmad Pharmacist
Anisah Ahmad Pharmacist
by genevieve
01904 72(4328). Anticoagulants . Warfarin . Novel ...
Direct oral anticoagulant (DOAC) haemorrhage protocol
Direct oral anticoagulant (DOAC) haemorrhage protocol
by brianna
1. Contact haematologist on call. , document DOAC ...
Abbreviations: AF: atrial fibrillation, ACS: acute coronary syndrome, BD: twice daily, CAD: corona
Abbreviations: AF: atrial fibrillation, ACS: acute coronary syndrome, BD: twice daily, CAD: corona
by holly
CrCl. : creatinine clearance, CTO: chronic total o...
28 th August 2022 Ganesan Karthikeyan, Stuart Connolly*,
28 th August 2022 Ganesan Karthikeyan, Stuart Connolly*,
by dorothy
Mpiko. . Ntsekhe. , Bongani . Mayosi. * and Salim...
COMPASS: Show Us the Way for Medical Management of PAD
COMPASS: Show Us the Way for Medical Management of PAD
by miller
Clinical Associate Professor of Medicine. SSM Heal...
DentalUpdateNovember 2015A New Generation of Antiplatelet and Anticoag
DentalUpdateNovember 2015A New Generation of Antiplatelet and Anticoag
by cecilia
Steven Johnston, BDS, MSc, MFDS RCS(Ed), Dental Of...
P erioperative management of anticoagulated geriatric patients with
P erioperative management of anticoagulated geriatric patients with
by TinyTeddy
hip fractures. Dr Linda Xu . linda.xu@health.nsw.g...